Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.47 |
| ▸ | PKM | P14618 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | ALPL | P05186 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CCR1 | P32246 | 3/20 | 0.47 |
| ▸ | CCR5 | P51681 | 3/20 | 0.47 |
| ▸ | CCR8 | P51685 | 3/20 | 0.47 |
| ▸ | METAP1 | P53582 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8311607 | 0.81 | KDM4E (0.56) | SMN1; SMN2NPC1RAB9ATDP1PKM | |
| SCHEMBL28406387 | 0.78 | CBFB (0.47) | SMN1; SMN2NPC1RAB9ATDP1PKM | |
| SCHEMBL3327100 | 0.78 | KDM4E (0.49) | SMN1; SMN2NPC1RAB9ATDP1PKM | |
| SCHEMBL14157267 | 0.78 | NPC1 (0.47) | SMN1; SMN2NPC1RAB9ATDP1PKM | |
| SCHEMBL28397335 | 0.77 | CCR1 (0.51) | SMN1; SMN2NPC1RAB9ATDP1PKM | |
| SCHEMBL5493272 | 0.76 | NPC1 (0.54) | SMN1; SMN2NPC1RAB9ATDP1PKM | |
| SCHEMBL28406670 | 0.76 | NOTUM (0.63) | SMN1; SMN2NPC1RAB9APKML3MBTL1 | |
| Pyridine SCHEMBL29135857 | 0.75 | METAP1 (0.48) | SMN1; SMN2NPC1RAB9ATDP1PKM | |
| SCHEMBL17280240 | 0.75 | SMN1; SMN2 (0.49) | SMN1; SMN2NPC1RAB9ATDP1PKM | |
| SCHEMBL24575850 | 0.74 | METAP1 (0.46) | SMN1; SMN2NPC1RAB9ATDP1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015035062-A1 | ANTIPROLIFERATIVE COMPOUNDS | GENENTECH, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| US-6514966-B2 | Neuropeptide Y antagonists such as 2-chloro-5-(4-(3,4-dich loro-phenyl)-1H-imidazol-2-yl)-pyridine | PFIZER INC. | 2003-02-04 | — | — | US | disclosed |
| US-6355635-B1 | IMIDAZOLEBENZENE, IMIDAZOLEPYRIDINE COMPOUNDS FOR TREATMENT OF OBESITY | PFIZER INC. | 2002-03-12 | — | — | US | disclosed |
| US-20010039277-A1 | Compounds for the treatment of obesity | ELLIOTT RICHARD L (US) | 2001-11-08 | — | — | US | disclosed |
| WO-2000066578-A1 | COMPOUNDS FOR THE TREATMENT OF OBESITY | PFIZER PRODUCTS INC. (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039277-A1 | Compounds for the treatment of obesity | NPY1R, NPY4R, NPY2R | SMN1; SMN2 3943/4885NPC1 1762/4885RAB9A 3108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.